Mercy Now Using New Stent for Coronary Artery Disease
Mercy Medical Center in Sioux City, Iowa, used its first commercial implant of the newly FDA-approved Medtronic Resolute Onyx Drug-Eluting Stent (DES) in June. Mercy is the only hospital in the area to use the new drug–eluting stent for patients with coronary artery disease.
“This stent is easier for the interventional cardiologist to guide through areas of the vessel that previously would have been difficult to maneuver through,” said Mike McCarthy, Director of Mercy’s Heart Hospital.
The Resolute Onyx DES is the first and only DES to feature Core Wire Technology, an evolution of Continuous Sinusold Technology (CST). CST is a unique Medtronic method of stent manufacturing, which involves forming a single strand of cobalt alloy wire into a sinusoidal wave to construct a stent. This enables greater deliverability and conformability to the vessel wall. With Core Wire Technology, a radiopaque inner core is incorporated within the cobalt alloy wire to enhance visibility for accurate stent placement. The technology also enables thinner struts while maintaining structural strength.
With the first 4.5 mm and 5.0 mm DES sizes available, the Resolute Onyx DES helps expand treatment options for patients with extra-large vessels. In addition, it is designed with the transradial approach in mind, including 5 F catheter compatibility with stent sizes up to 5.0 mm.
The Resolute Onyx DES is supported by the RESOLUTE ONYX Core (2.25 mm – 4.0 mm) Clinical Study as well as the long-term safety and efficacy with low stent-thrombosis rates in the Global RESOLUTE Clinical Program. It uses the BioLinx polymer – specifically designed for DES – that features a unique hydrophilic and hydrophobic blend, allowing rapid endothelial healing with minimal inflammation and low risk of stent thrombosis.